The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury
Abstract
Neuroprotection is one of the core treatment strategies for brain injuries including traumatic brain injury (TBI). NR2B9c is a promising neuroprotective peptide but its clinical translation is limited because of poor brain penetrability. Exosomes are naturally occurring nanovesicles having therapeutic potential for TBI as well as an efficient drug delivery carrier to the brain. Here, we engineered exosomes with neuron targeting peptide rabies virus glycoprotein (RVG29) via bio-orthogonal click chemistry technique and loaded it with NR2B9c, developing RVG-Exo NR2B9c . RVG29 conjugated exosome had higher neuron targeting efficiency compared to naïve exosomes both in vivo and in vitro. RVG-Exo NR2B9c had great cytoprotective effect against oxygen glucose deprived Neuro2a cells. Intravenous administration of RVG-Exo NR2B9c significantly improved behavioral outcomes and reduced the lesion volume after TBI injury in a mice controlled cortical impact model. Due to their multifunctionality and significant efficacy, we anticipate that RVG-Exo NR2B9c have the potential to be translated both as therapeutic agent as well as cargo delivery system to the brain for the treatment of TBI.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Haroon et al. coupled rabies virus glycoprotein 29 with the small EVs surface to increase neuron targeting efficiency and treatment for brain injuries including traumatic brain injury and ischemic stroke [26, 34].”
From Engineered Extracellular Vesicles Loaded with MiR-100-5p Antagonist Selectively Target the Lesioned Region to Promote Recovery from Brain Damage (2025) · cites this paper as [34]
Citations
Cites
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Excitotoxicity and stroke: Identifying novel targets for neuroprotection
Lai, T. W., Zhang, S., & Wang, Y. T. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.006 · Cited by 1,106
Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions
Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J. W., Wang, Y.-T., Salter, M. W., & Tymianski, M. (2002) · Science · doi:10.1126/science.1072873 · Cited by 999
Self-citationCurrent Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Specific Coupling of NMDA Receptor Activation to Nitric Oxide Neurotoxicity by PSD-95 Protein
Sattler, R., Xiong, Z., Lu, W.-Y., Hafner, M., MacDonald, J. F., & Tymianski, M. (1999) · Science · doi:10.1126/science.284.5421.1845 · Cited by 834
Hill, M. D., Goyal, M., Menon, B. K., Nogueira, R. G., McTaggart, R. A., Demchuk, A. M., Poppe, A. Y., Buck, B. H., Field, T. S., Dowlatshahi, D., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30258-0 · Cited by 647
Self-citationExosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 604
Scinto, S. L., Bilodeau, D. A., Hincapie, R., Lee, W., Nguyen, S. S., Xu, M., am Ende, C. W., Finn, M. G., Lang, K., Lin, Q., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00028-z · Cited by 592
Cited by
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26
Cheng, Y., Gai, C., Zhao, Y., Li, T., Song, Y., Luo, Q., Xin, D., Jiang, Z., Chen, W., Liu, D., et al. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01376-6 · Cited by 5
Metadata
- Authors
- Haroon, K., Zheng, H., Wu, S., Liu, Z., Tang, Y., Yang, G.-Y., Liu, Y., & Zhang, Z.
- Venue
- International Journal of Pharmaceutics
- Publisher
- Elsevier BV
- Published
- 2024-01
- Volume
- 649
- Pages
- 123656
- ISSN
- 0378-5173
- Cited by
- 48
- References
- 49
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- National Natural Science Foundation of China (82271320, 82371307, 81974179, 82071284, 8217030178)
- Shanghai Rising-Star Program (21QA1405200)
- Innovative Research Group Project of the National Natural Science Foundation of China
- National Key Research and Development Program of China (2019YFA0112000, 2022YFA1603604)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury. https://app.cochat.ai/papers/10.1016/j.ijpharm.2023.123656
- The paper
- Haroon, K., Zheng, H., Wu, S., Liu, Z., Tang, Y., Yang, G.-Y., Liu, Y., & Zhang, Z. (2024). Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury. International Journal of Pharmaceutics. https://doi.org/10.1016/j.ijpharm.2023.123656
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.